Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF9001 as a Monotherapy and in Combination Therapies in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications

NCT05597839 is registered in ClinicalTrials.gov with Dragonfly Therapeutics as lead sponsor.

NCT NCT05597839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05597839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF9001 as a Monotherapy and in Combination Therapies in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications
Lead sponsor
Dragonfly Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
November 15, 2022
Completion date
August 15, 2025
Enrollment
24 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult